Summary
The C-terminus of the insulin B chain is essential for dimerisation and expression of negative cooperativity. In order to evaluate the possible physiological role of these phenomena, we have studied the properties in vivo and in vitro of despentapeptide insulin (B 26–30 deleted), derived from beef insulin, and deshexapeptide insulin (B25–30 deleted), derived from pork insulin. These materials do not dimerise and have 15% and 0% retention of negative cooperativity respectively. Lipogenesis potencies in rat adipocytes were: despentapeptide insulin 19.9±0.3%; deshexapeptide insulin 19.9±1.5%. Binding potencies in adipocytes were: despentapeptide insulin 22.6±7.8%; deshexapeptide insulin 13.2±3.3%. Metabolic clearance rates were reduced compared to insulin (insulin = 19.1±0.9; despentapeptide insulin = 9.7±0.8; deshexapeptide insulin = 6.4±0.6ml·min−1·kg−1 at plasma concentration 0.5 nmol/l). Hypoglycaemic potencies were reduced for both analogues (40% and 30%) when calculated on the basis of plasma concentration although both analogues and insulin were equally effective at lowering plasma glucose concentration in equimolar doses. Plasma half-disappearance time was prolonged (despentapeptide insulin=7.3±0.5; deshexapeptide insulin=9.1±0.2 min). Both analogues were full agonists and conformed to the general relationship between in vitro and in vivo properties seen with a wide range of modified insulins. They resemble other analogues with modifications which reduce receptor affinity without impairing dimerisation or negative cooperativity. The results do not support a physiological role for dimerisation or negative cooperativity.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
De Meyts P, Bianco AR, Roth J (1976) Site-site interactions among insulin receptors. Characterization of the negative cooperativity. J Biol Chem 251: 1877–1888
De Meyts P, Van Obberghen E, Roth J, Wollmer A, Brandenburg D (1978) Mapping of the residues responsible for the negative cooperativity of the receptor-binding region of insulin. Nature; 273: 504–509
Saunders D (1982) A new interpretation of structure-function relationhips in insulin-receptor interactions. Diabetologia 23: 386–390
Shanghai Insulin Research Group, Shanghai Institute of Biochemistry, Academia Sinica (1977) Studies on the structure — function relationship of insulin. III further studies on Des (B25-30)-Insulin and its analog. Acta Biochem Biophys Sin 9: 169–173
De Meyts P, Gu JL, Keefer LM, Naithani K, Gattner HG, Brandenburg D (1982) Positive and negative control of the dissociation rate of insulin receptors by structural analogues of insulin. Excerpta Medica 577 (11th Congress of the International Diabetes Federation), p 128
Liang DC, Dai JB, Stuart D, Wan ZL, Todd R, You JM, Lou MZ (1983) Some problems in relation to the structures of insulin derivatives. Biochem Soc Trans 11: 419–425
Bi RC, Dauter Z, Dodson E, Dodson G, Gordiano F, Hubbard R, Reynolds C (1983) Structural changes in the monomeric despentapeptide (B30–B36) insulin crystal. Proc Ind Acad Sci 92: 473–483
Bi RC, Dauter Z, Dodson E, Dodson G, Gordiano F, Reynolds C (1984) Insulin's structure as a modified and monomeric molecule. Biopolymers 23: 391–395
Gattner HG (1975) B-Kettenverkürzung von polymergebundenem Insulin mit Pepsin, I. Darstellung und Eigenschaften von Des-pentapeptid B26–30-Rinderinsulin. Hopper Seyler's Z Physiol Chem 356 (9): 1397–1404
Cao QP, Cui DF, Zhang YS (1981) Enzymatic synthesis of deshexapeptide insulin. Nature 292: 774–775
Gan YX, Cao QP, Zhang YS (1983) Separation and identification of insulin and its analogues by high performance liquid chromatography, kexue Tongbao 28: 1536–1540
Cockram CS, Jones RH, Sonksen PH (1985) The biological properties of insulins with tyrosine replaced by phenylalanine at positions 14 and 19 of the A chain. Diabetic Med 2: 241–244
Gliemann J (1967) Assay of insulin-like activity by the isolated fat cell method: 1 Factors influencing the response to crystalline insulin. Diabetologia 3: 382–388
Rodbell M (1964) Metabolism of isolated fat cells: 2 Effects of hormones on glucose metabolism and lipolysis. J Biol Chem 239: 375–380
Moody AJ, Stan MA, Stan M, Gliemann J (1974) A simple free fat cell bioassay for insulin. Horm Metab Res 6: 12–16
Finney DJ (1964) Statistical methods in biological assay, 2nd edn. Griffin, London, pp 99–138
Linde S, Hansen B, Sonne O, Holst JJ, Gliemann J (1981) Tyrosine A14-[125I]-monoiodoinsulin. Preparation, biologic properties and long-term stability. Diabetes 30: 1–8
Jones RH, Dron DI, Ellis MJ, Sonksen PH, Brandenburg D (1976) Biological properties of chemically modified insulins. I Biological activity of proinsulin and insulin modified at A1-glycine and B29-lysine. Diabetologia 12: 601–608
Sonksen PH (1976) Separation of antibody-bound from free hormone by the double-antibody technique. In: Antoniades HN (ed) Hormones in human blood. Detection and assay. Harvard University Press, pp 121–138
Tatnell MA, Jones RH, Sonksen PH (1984) Covalently linked insulin dimers: their metabolism and biological effects in vivo as partial competitive antagonists of insulin clearance. Diabetologia 27: 27–31
Fischer WH, Saunders D, Brandenburg D, Wollmer A, Zahn H (1985) A shortened insulin with full in vitro potency. Biol Chem Hoppe-Seyler 366: 521–525
Cui DP, Cao QP, Zhu SQ, Zhang XT, Zhang YS (1983) Enzymatic synthesis of deshexapeptide insulin and its analogues. Sci Sin [B] 26: 248–154
Rieman MW, Pon LA, Carpenter FH (1983) Preparation of semisynthetic insulin analogues from bis(tert-butyloxycarbonyl)-desoctapeptide insulin phenylhydrazide: importance of the aromatic region B24-B26. Biochemistry 22: 1507–1515
Papachristodoulou D, Brandenburg D, Dron DI, Jones RH, Sonksen PH, Thomas JH (1977) Studies on the relationship between the molecular structure and the catabolism of insulin. Acta Biol Med Germ 36: 1705–1712
Dron DI, Jones RH, Sonksen PH, Thomas JH and Brandenburg D (1980) Radioimmunoassay of chemically-modified insulins. Diabetologia 18: 59–63
Ellis MJ, Jones RH, Thomas JH, Geiger R, Teetz V, Sonksen PH (1977) B1–3, 5-diiodotyrosine insulin: a valid tracer for insulin. Diabetologia 13: 257–261
Shvachkin Yu P, Shmeleva GA, Krivtsov VF, Fedotov VP, Ivanova AI (1972) Isolation and properties of des-(pentapeptide-B26–30)-insulin. Biokhimiya 37: 966–973
Olefsky JM, Green A, Ciraldi TP, Saekow M, Rubinstein AH, Tager HS (1981) Relationship between negative cooperativity and insulin action. Biochemistry 20: 4488–4492
Keefer LM, Piron MA, De Meyts P, Gattner HG, Diaconescu C, Saunders D, Brandenburg D (1981) Impaired negative cooperativity of the semisynthetic analogues human [leuB24]- and [leuB25]-insulins. Biochem Biophys Res Comm 100: 1229–1236
Kobayashi M, Ohgaku S, Iwasaki M, Maegawa H, Shigeta Y, Inouye K (1982) Supernormal insulin: [D-PheB24]-insulin with increased affinity for insulin receptors. Biochem Biophys Res Comm 107: 329–336
Insulin Research Group, Shanghai Institute of Biochemistry, Academia Sinica et al (1976) Structural studies on des-pentapeptide (B26–30)-insulin, I. The preparation and properties of despentapeptide insulin. Sci Sin 19: 351–357
Katsoyannis PG, Ginos J, Schwarz GP, Cosmatos A (1974) Synthesis of a biologically active truncated insulin. Des (pentapeptide B23–30) human (porcine) insulin. J Chem Soc 1311–1317
Weitzel G, Bauer FU, Eisele K (1976) Further studies on the three-step increase in activity due to the aromatic amino acids B24–26. Hoppe Seylers Z Physiol Chem 357: 187–200
Inouye K, Watanabe K, Tochino Y, Kobayashi M, Shigeta Y (1981) Semisynthesis and properties of some insulin analogues. Biopolymers 20: 1845–1858
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cockram, C.S., Jones, R.H., Sonksen, P.H. et al. An examination of the role of insulin dimerisation and negative cooperativity using the biological properties of the despentapeptide and deshexapeptide insulins. Diabetologia 30, 733–738 (1987). https://doi.org/10.1007/BF00296998
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00296998